SUNIL AGARWAL - 23 Jan 2026 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role: Director
Signature: /s/ Ben Harshbarger, as attorney-in-fact for Sunil Agarwal
Issuer symbol: ATXS
Transactions as of: 23 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 23 Jan 2026, 16:15:41 UTC
Previous filing: 30 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
AGARWAL SUNIL	Director	C/O ASTRIA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON	/s/ Ben Harshbarger, as attorney-in-fact for Sunil Agarwal	23 Jan 2026	0001616640

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATXS	Stock Option (Right to Buy)	Disposed to Issuer		-28,200	-100%		0	23 Jan 2026	Common Stock	28,200	$11.40	Direct	F1
transaction	ATXS	Stock Option (Right to Buy)	Disposed to Issuer		-26,550	-100%		0	23 Jan 2026	Common Stock	26,550	$5.79	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

SUNIL AGARWAL is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

Content

Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.